Genomics of Dementia : APOE- and CYP2D6-Related Pharmacogenetics

Joint Authors

Tellado, Iván
Lombardi, Valter R. M.
Corzo, Lola
Cacabelos, Ramón
McKay, Adam
Carril, Juan C.
Fernández-Novoa, Lucía
Leszek, Jerzy
Martínez, Rocío
Carrera, Iván
Takeda, Masatoshi

Source

International Journal of Alzheimer's Disease

Issue

Vol. 2012, Issue 2012 (31 Dec. 2012), pp.1-37, 37 p.

Publisher

Hindawi Publishing Corporation

Publication Date

2012-03-14

Country of Publication

Egypt

No. of Pages

37

Main Subjects

Diseases
Medicine

Abstract EN

Dementia is a major problem of health in developed societies.

Alzheimer’s disease (AD), vascular dementia, and mixed dementia account for over 90% of the most prevalent forms of dementia.

Both genetic and environmental factors are determinant for the phenotypic expression of dementia.

AD is a complex disorder in which many different gene clusters may be involved.

Most genes screened to date belong to different proteomic and metabolomic pathways potentially affecting AD pathogenesis.

The ε4 variant of the APOE gene seems to be a major risk factor for both degenerative and vascular dementia.

Metabolic factors, cerebrovascular disorders, and epigenetic phenomena also contribute to neurodegeneration.

Five categories of genes are mainly involved in pharmacogenomics: genes associated with disease pathogenesis, genes associated with the mechanism of action of a particular drug, genes associated with phase I and phase II metabolic reactions, genes associated with transporters, and pleiotropic genes and/or genes associated with concomitant pathologies.

The APOE and CYP2D6 genes have been extensively studied in AD.

The therapeutic response to conventional drugs in patients with AD is genotype specific, with CYP2D6-PMs, CYP2D6-UMs, and APOE-4/4 carriers acting as the worst responders.

APOE and CYP2D6 may cooperate, as pleiotropic genes, in the metabolism of drugs and hepatic function.

The introduction of pharmacogenetic procedures into AD pharmacological treatment may help to optimize therapeutics.

American Psychological Association (APA)

Cacabelos, Ramón& Martínez, Rocío& Fernández-Novoa, Lucía& Carril, Juan C.& Lombardi, Valter R. M.& Carrera, Iván…[et al.]. 2012. Genomics of Dementia : APOE- and CYP2D6-Related Pharmacogenetics. International Journal of Alzheimer's Disease،Vol. 2012, no. 2012, pp.1-37.
https://search.emarefa.net/detail/BIM-478114

Modern Language Association (MLA)

Cacabelos, Ramón…[et al.]. Genomics of Dementia : APOE- and CYP2D6-Related Pharmacogenetics. International Journal of Alzheimer's Disease No. 2012 (2012), pp.1-37.
https://search.emarefa.net/detail/BIM-478114

American Medical Association (AMA)

Cacabelos, Ramón& Martínez, Rocío& Fernández-Novoa, Lucía& Carril, Juan C.& Lombardi, Valter R. M.& Carrera, Iván…[et al.]. Genomics of Dementia : APOE- and CYP2D6-Related Pharmacogenetics. International Journal of Alzheimer's Disease. 2012. Vol. 2012, no. 2012, pp.1-37.
https://search.emarefa.net/detail/BIM-478114

Data Type

Journal Articles

Language

English

Notes

Includes bibliographical references

Record ID

BIM-478114